Mesoblast Ltd ADR MESO

$10.89 -0.29 (-2.59%)

Valuation

Market cap
1,454,854,000
Revenue TTM
$120,250,000
Net income TTM
$-57,500,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-47.82%
Debt to equity
0.21

Trading

Volume
192,700
Avg volume
253,790
Day's range
$10.87 – $11.44
Shares out
130,130,000
Stochastic %K
1%
Beta
2.21
Analysts
Strong Buy
Price target
$37.00

Price

Company profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy...

Show more

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Industry
Biotechnology
Sector
Healthcare
Phone
61 3 9639 6036
Website
https://www.mesoblast.com
Address
55 Collins Street, Level 38, Melbourne, Australia

Latest news

Stocktwits

PB09 Nov 21, 8:53 AM
Here is some Hopium $CAPR — still see a possible path here. * HOPE-3 published in The Lancet * Trial doctors publicly backed approval * Patient/family testimony at AdCom * Eliquis ($BMY/$PFE), Ryoncil ($MESO), Vyondys 53 ($SRPT): CRLs → eventual approvals FDA says HOPE-3’s data issues can’t be fixed after the fact. Serious hurdle. Tell them What actually happened, using original records. The scope and timing of any loss of blinding. Who had access to treatment information when analytical changes were made. Whether an acceptable analysis of reliable data still supports efficacy. Whether FDA agrees that the problems have been adequately bounded. Still believe eventual approval is possible if CAPR can establish a path FDA will accept.
1 replies
Diane3825 Nov 16, 2:33 PM 0 replies
dixiebull Nov 15, 11:19 PM 0 replies
StocktwitsEarnings Nov 5, 10:00 PM
$MESO Q1 '27 Earnings Results & Recap Mesoblast reported first-quarter FY2027 RYONCIL net revenue of US$28M, up 44% year over year, and US$2.1M operating cash spend, an 86% improvement; cash was US$99M.
1 replies
Diane3825 Oct 30, 1:06 PM
$CAPR $MESO Capricor has responded to the Mesoblast patent infringement lawsuit. They have requested and been granted an extension in their full response to November 24, 2026. Interesting timing on that being 2 days after the PDUFA date.
0 replies
JuliusCoolius Oct 30, 12:54 AM
$MESO seems like there are no US retail investors left. Stock is up double digit percentage and not a single post about it. Is it bullish that mostly institutions own this now, or bearish? Asking into the ether.
2 replies
Diane3825 Oct 29, 2:24 PM 0 replies
Diane3825 Oct 29, 2:24 PM 0 replies